Peer-reviewed veterinary case report
Skeletal muscle cell transplant improved heart function in dogs
By He, Kun-Lun et al.·Published in The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2005·Department of Cardio-Nephrology, China·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Autologous skeletal myoblast transplantation improved hemodynamics and left ventricular function in chronic heart failure dogs.
- Species:
- dog
Plain-English summary
A group of dogs with chronic heart failure (CHF) received injections of their own muscle cells (myoblasts) to see if it would help their heart function. After 10 weeks, the dogs that got the myoblast injections showed better heart performance compared to those that received a saline injection. Specifically, their heart's ability to pump blood improved, and there were signs that their heart structure was returning to a more normal state. While the treatment showed some positive effects, it was noted that the injected cells did not appear to survive in the heart tissue.
People also search for: dog heart failure treatment · improving heart function in dogs · myoblast therapy for dogs · chronic heart failure in dogs · dog heart problems symptoms
Abstract
BACKGROUND: Previous studies have suggested that autologous skeletal myoblast transplantation (ASMT) improves left ventricular (LV) function in small animals after myocardial infarction. We tested the effects of ASMT on hemodynamics, LV function and remodeling in coronary microembolization-induced chronic heart failure (CHF) in conscious dogs. METHODS: Nineteen dogs were continuously instrumented with LV pressure sensors and mid-myocardial sonomicrometry crystals for dP/dt(max) and LV volume determination. Each dog underwent baseline assessment in a conscious state. CHF (20% to 30% reduction in dP/dt(max) and LV end-diastolic pressure >16 mm Hg) was created by daily coronary microembolizations via a continuously implanted coronary catheter. Skeletal muscle biopsy was performed and myoblasts were isolated and expanded. Then 2.7 x 10(8) to 8.3 x 10(8) myoblasts were injected into the infarcted region of 11 dogs after establishment of CHF. Saline injection (sham) was performed in 8 control dogs. Animals were evaluated every 2 weeks for up to 10 weeks. Global ejection fraction was determined by echocardiography. The end-systolic pressure-end-systolic volume relationship (ESPVR) was analyzed by the Sonomicrometic system. RESULTS: Compared with saline injection, ASMT significantly increased dP/dt(max) (105 +/- 9% vs 97 +/- 7%, values were expressed as percentage change from baseline CHF, p = 0.013) and ejection fraction (46 +/- 3% vs 40 +/- 2%, p = 0.034) at 10 weeks after myoblast transplantation. There was a significant leftward and upward shift of the ESPVR back toward normal at 10 weeks after myoblast transplantation (p = 0.034). Three animals labeled with BrdU myoblasts showed no histologic evidence of viable engraftment. CONCLUSIONS: ASMT provided mild improvements in hemodynamics and LV function and reduced LV remodeling in conscious dogs with CHF.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/16297802/